LAUSR

Gefitinib reduces oocyte quality by disturbing meiotic progression.

Sign Up to like & get
recommendations!
0 Published in 2021 at "Toxicology"

DOI: 10.1016/j.tox.2021.152705

Abstract: Gefitinib is a first-line anti-cancer drug for the treatment of advanced non-small cell lung cancer (NSCLC). It has been reported that gefitinib can generate several drug-related adverse effects, including nausea, peripheral edema, decreased appetite and… read more here.

Keywords: gefitinib; meiotic progression; oocyte quality; gefitinib reduces ... See more keywords